Hepatic enhancement and signal intensity analysis on magnetic resonance imaging as prognostic biomarkers in advanced chronic liver disease

Table 9 Diagnostic performance of hepatic enhancement, Functional Liver Imaging Score, and clinical scores for predicting decompensation: Receiver operating characteristic curve analysis results¹

Marker	AUC (95%CI)	Youden cut-off	Se	Sp	PPV	NPV	Δ HE vs FLIS (q)	Δ HE vs MELD 3.0 (q)	Δ HE vs ALBI (q)
FLIS	0.79 (0.69-0.88)	4.5	0.76	0.76	0.57	0.88	-	-	-
MELD 3.0	0.73 (0.63-0.86	18.5	0.43	0.94	0.8	0.74	-	-	-
ALBI	0.77 (0.68-0.86	-2.1	0.70	0.73	0.60	0.81	-	-	-
HE segment VI	0.74 (0.62-0.85)	75	0.68	0.86	0.64	0.88	-0.05 (0.123)	0.01 (0.964)	-0.04 (0.580)
HE segment VIII	0.68 (0.55-0.79)	67.5	0.43	0.86	0.64	0.72	-0.08 (0.014)	-0.05 (0.400)	-0.09 (0.400)
HE segment III	0.68 (0.56-0.79)	65	0.51	0.82	0.63	0.74	-0.08 (0.003)	-0.05 (0.400)	-0.09 (0.400)
HE caudate lobe	0.70 (0.59-0.81)	82.5	0.60	0.76	0.60	0.76	-0.11 (0.017)	-0.03 (0.616)	-0.07 (0.400)
HE global	0.71 (0.60-0.82)	86.3	0.70	0.71	0.59	0.81	-0.11 (0.023)	-0.02 (0.671)	-0.06 (0.400)

¹q: P-values adjusted using false discovery rate via the Benjamini-Hochberg test. False discovery rate-significant at q ≤ 0.05.

Δ: Area under the curve difference; ALBI: Albumin-Bilirubin score; AUC: Area under the curve; CI: Confidence interval; FLIS: Functional Liver Imaging Score; HE: Hepatic enhancement; MELD 3.0: Model for End-Stage Liver Disease 3.0; NPV: Negative predictive value; PPV: Positive predictive value; Se: Sensitivity; Sp: Specificity.